ReviewJournal of clinical microbiology2019
Cost-Effective Respiratory Virus Testing.
Review in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Pathogen trends and paradigm shifts of respiratory infections in children: a 5-year retrospective study from Perugia.Italian journal of pediatrics · 2026Article
- Current Evidence and Gaps for Outpatient Respiratory Tract Infection Diagnostics: A Call to Action.Open forum infectious diseases · 2025Article
- Rapid diagnosis of acute pediatric respiratory infections with Point-of-Care and multiplex molecular testing.Infection · 2025Review
- A Novel Multiplex LAMP Assay for the Detection of Respiratory Human Adenoviruses.International journal of molecular sciences · 2024Article
- Exploring the Impact of Antibiotics on Fever Recovery Time and Hospital Stays in Children with Viral Infections: Insights from Advanced Data Analysis.Antibiotics (Basel, Switzerland) · 2024Article
- Commentary on the adoption of a test-based versus syndromic-based approach to outbreak declaration and management in hospital and institutional settings.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024Article
- Review
- Predominant SARS-CoV-2 variant impacts accuracy when screening for infection using exhaled breath vapor.Communications medicine · 2022Article
- BD MAX Enteric Bacterial, Bacterial Plus, and Virus Panels for Diagnosis of Acute Infectious Gastroenteritis: a Cost-Benefit Analysis.Microbiology spectrum · 2022Article
- Self-medication and ILI etiologies among individuals presenting at pharmacies with influenza-like illness: Guatemala City, 2018 influenza season.BMC public health · 2022Article
- Rapid Antigen Assays for SARS-CoV-2: Promise and Peril.Clinics in laboratory medicine · 2022Review
- Introducing antimicrobial stewardship to the outpatient clinics of a suburban academic health system.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Cost-Effectiveness Analysis of Rapid Test Compared to Polymerase Chain Reaction (PCR) in Patients with Acute Respiratory Syndrome.Medical journal of the Islamic Republic of Iran · 2022Article
- Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2.Frontiers in microbiology · 2022Article
- Viral Coinfection is Associated with Improved Outcomes in Emergency Department Patients with SARS-CoV-2.The western journal of emergency medicine · 2021Article
- Patient, Provider, and Health Care System Characteristics Associated With Overuse in Bronchiolitis.Pediatrics · 2021Article
- Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases.The Journal of antimicrobial chemotherapy · 2021Review
- The Need for Dedicated Microbiology Leadership in the Clinical Microbiology Laboratory.Journal of clinical microbiology · 2021Article
- Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging Pathogens.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The timely and accurate diagnosis of respiratory virus infections has the potential to optimize downstream (posttesting) use of limited health care resources, including antibiotics, antivirals, ancillary testing, and inpatient and emergency department beds. Cost-effective algorithms for respiratory virus testing must take into consideration numerous factors, including which patients should be tested, what testing should be performed (for example, antigen testing versus reverse transcription-PCR testing or influenza A/B testing versus testing with a comprehensive respiratory virus panel), and the turnaround time necessary to achieve the desired posttesting outcomes. Despite the clinical impact of respiratory virus infections, the cost-effectiveness of respiratory virus testing is incompletely understood. In this article, we review the literature pertaining to the cost-effectiveness of respiratory virus testing in pediatric and adult patient populations, in emergency department, outpatient, and inpatient clinical settings. Furthermore, we consider the cost-effectiveness of a variety of testing methods, including rapid antigen tests, direct fluorescent antibody assays, and nucleic acid amplification tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.